-
公开(公告)号：US20130287778A1
公开(公告)日：2013-10-31
申请号：US13881889
申请日：2011-10-27
申请人： Gerhard Zugmaier , Dirk Nagorsen , Juergen Scheele
发明人： Gerhard Zugmaier , Dirk Nagorsen , Juergen Scheele
IPC分类号： A61K39/395
CPC分类号： C07K16/2809 , A61K39/39558 , A61K2039/505 , A61K2039/545 , C07K16/2803 , C07K2317/31 , C07K2317/76
摘要： The present invention provides means and methods for treating diffuse large B cell lymphoma (DLBCL). Specifically, a bispecific CD19×CD3 antibody which engages T cells via its CD3 binding portion and concomitantly binds to CD19 on the surface of in particular, lymphoma cells via its CD19 binding portion (i.e. a bispecific T cell engager, “BiTE”) is administered for use in the treatment of tumorous mass of lymophoreticular tissue and/or extranodal lymphoma caused by DLBCL in a patient.
摘要翻译： 本发明提供了治疗弥漫性大B细胞淋巴瘤（DLBCL）的方法和方法。 具体地，施用通过其CD3结合部分与T细胞接合并通过其CD19结合部分特别是淋巴瘤细胞表面（即双特异性T细胞募集体“BiTE”）并与CD19结合的双特异性CD19×CD3抗体） 用于治疗由DLBCL引起的淋巴管组织和/或结外淋巴瘤的肿瘤组织。
-
2.发明申请公开(公告)号：US20130287774A1
公开(公告)日：2013-10-31
申请号：US13884497
申请日：2011-10-27
申请人： Gerhard Zugmaier , Dirk Nagorsen , Juergen Scheele
发明人： Gerhard Zugmaier , Dirk Nagorsen , Juergen Scheele
IPC分类号： A61K31/573 , A61K39/395
CPC分类号： A61K31/573 , A61K39/3955 , A61K39/39558 , A61K2039/505 , A61K2300/00 , C07K16/2803 , C07K16/2809 , C07K2317/31
摘要： The present invention relates to a glucocorticoid (GC) for use in the amelioration, treatment or prophylaxis of neurological/psychiatric adverse events caused by a CD3 binding domain. Kits comprising a GC, a CD3 binding domain and instructions for use which indicate that the GC is to be employed for the treatment amelioration and/or prophylaxis of neurological adverse events caused by said CD3 binding domain, are also disclosed.
摘要翻译： 本发明涉及用于改善，治疗或预防由CD3结合结构域引起的神经/精神不良事件的糖皮质激素（GC）。 还公开了包含GC，CD3结合结构域的试剂盒和用于指示GC用于治疗由所述CD3结合结构域引起的神经功能不良事件的改善和/或预防的使用说明书。
-
公开(公告)号：US20070037228A1
公开(公告)日：2007-02-15
申请号：US11438033
申请日：2006-05-19
IPC分类号： G01N33/574
CPC分类号： G01N33/57415 , C12Q1/6886 , C12Q2600/106 , C12Q2600/136 , C12Q2600/158 , G01N33/6872 , G01N2333/4756 , G01N2333/485 , G01N2333/495 , G01N2800/52
摘要： The invention is related to a method of predicting the response to a treatment with a HER inhibitor in a patient comprising the steps of assessing a biomarker or a combination of biomarkers selected from the group consisting of amphiregulin, an epidermal growth factor, a transforming growth factor alpha, and a HER2 biomarker in a biological sample from the patient and predicting the response to the treatment with the HER inhibitor in the patient by evaluating the results of the first step. Further uses and methods wherein these markers are used are disclosed.
摘要翻译： 本发明涉及预测患者中用HER抑制剂治疗反应的方法，其包括以下步骤：评估生物标志物或生物标志物的组合，所述生物标志物或选自下组的生物标志物组合，所述生物标志物是由两性调节蛋白，表皮生长因子，转化生长因子 α和来自患者的生物样品中的HER2生物标志物，并通过评估第一步的结果预测患者中用HER抑制剂治疗的反应。 公开了其中使用这些标记的其它用途和方法。
-
公开(公告)号：US09192665B2
公开(公告)日：2015-11-24
申请号：US13881889
申请日：2011-10-27
申请人： Gerhard Zugmaier , Dirk Nagorsen , Juergen Scheele
发明人： Gerhard Zugmaier , Dirk Nagorsen , Juergen Scheele
IPC分类号： A61K39/395 , C07K16/28 , A61K39/00
CPC分类号： C07K16/2809 , A61K39/39558 , A61K2039/505 , A61K2039/545 , C07K16/2803 , C07K2317/31 , C07K2317/76
摘要： The present invention provides means and methods for treating diffuse large B cell lymphoma (DLBCL). Specifically, a bispecific CD19×CD3 antibody which engages T cells via its CD3 binding portion and concomitantly binds to CD19 on the surface of in particular, lymphoma cells via its CD19 binding portion (i.e. a bispecific T cell engager, “BiTE”) is administered for use in the treatment of tumorous mass of lymophoreticular tissue and/or extranodal lymphoma caused by DLBCL in a patient.
摘要翻译： 本发明提供了治疗弥漫性大B细胞淋巴瘤（DLBCL）的方法和方法。 具体地，施用通过其CD3结合部分与T细胞接合并通过其CD19结合部分特别是淋巴瘤细胞表面（即，双特异性T细胞募集体“BiTE”）同时结合CD19的双特异性CD19×CD3抗体） 用于治疗由DLBCL引起的淋巴管组织和/或结外淋巴瘤的肿瘤组织。
-
公开(公告)号：US08840888B2
公开(公告)日：2014-09-23
申请号：US13504665
申请日：2010-10-27
申请人： Dirk Nagorsen , Peter Kufer , Gerhard Zugmaier , Patrick Baeuerle
发明人： Dirk Nagorsen , Peter Kufer , Gerhard Zugmaier , Patrick Baeuerle
IPC分类号： A61K39/395 , G01N33/50 , C07K16/28 , A61K39/00
CPC分类号： C07K16/2809 , A61K2039/505 , A61K2039/545 , A61K2039/55 , C07K16/2803 , C07K2317/31 , G01N33/505 , G01N33/5052 , G01N33/5094 , G01N2800/52
摘要： Provided herein is a method for assessing the risk of potential adverse effects for a human patient mediated by the administration of a CD19.times.CD3 bispecific antibody to said patient comprising determining the ratio of B cells to T cells of said patient, wherein a ratio of about 1:5 or lower is indicative for a risk of potential adverse effects for said patient.
摘要翻译： 本文提供了一种用于评估通过向所述患者施用CD19×CD3族特异性抗体介导的对患者的潜在不良作用的风险的方法，包括测定所述患者的B细胞与T细胞的比例，其中比例 约1:5或更低，表示对所述患者具有潜在的不利影响的风险。
-
公开(公告)号：US10130638B2
公开(公告)日：2018-11-20
申请号：US13884497
申请日：2011-10-27
申请人： Gerhard Zugmaier , Dirk Nagorsen , Juergen Scheele
发明人： Gerhard Zugmaier , Dirk Nagorsen , Juergen Scheele
IPC分类号： A61K39/395 , A61K31/573 , C07K16/28 , A61K39/00
摘要： The present invention relates to a glucocorticoid (GC) for use in the amelioration, treatment or prophylaxis of neurological/psychiatric adverse events caused by a CD3 binding domain. Kits comprising a GC, a CD3 binding domain and instructions for use which indicate that the GC is to be employed for the treatment amelioration and/or prophylaxis of neurological adverse events caused by said CD3 binding domain, are also disclosed.
-
公开(公告)号：US20110262440A1
公开(公告)日：2011-10-27
申请号：US13127538
申请日：2009-11-06
申请人： Gerhard Zugmaier
发明人： Gerhard Zugmaier
IPC分类号： A61K39/395 , C07K16/28 , A61P35/02
CPC分类号： C07K16/2803 , A61K2039/505 , C07K16/2809 , C07K16/3061 , C07K16/468
摘要： The present invention relates to a method for the treatment, amelioration or elimination of pediatric acute lymphoblastic leukemia (ALL), the method comprising the administration of a pharmaceutical composition comprising a CD19×CD3 bispecific single chain antibody construct to a pediatric ALL patient in the need thereof.
摘要翻译： 本发明涉及一种治疗，改善或消除儿科急性淋巴细胞白血病（ALL）的方法，所述方法包括向需要的儿科ALL患者施用包含CD19×CD3双特异性单链抗体构建体的药物组合物 其中。
-
公开(公告)号：US20100112603A1
公开(公告)日：2010-05-06
申请号：US12624443
申请日：2009-11-24
IPC分类号： G01N33/53
CPC分类号： G01N33/57415 , C12Q1/6886 , C12Q2600/106 , C12Q2600/136 , C12Q2600/158 , G01N33/6872 , G01N2333/4756 , G01N2333/485 , G01N2333/495 , G01N2800/52
摘要： The invention is related to a method of predicting the response to a treatment with a HER inhibitor in a patient comprising the steps of assessing a biomarker or a combination of biomarkers selected from the group consisting of amphiregulin, an epidermal growth factor, a transforming growth factor alpha, and a HER2 biomarker in a biological sample from the patient and predicting the response to the treatment with the HER inhibitor in the patient by evaluating the results of the first step. Further uses and methods wherein these markers are used are disclosed.
摘要翻译： 本发明涉及预测患者中用HER抑制剂治疗反应的方法，其包括以下步骤：评估生物标志物或生物标志物的组合，所述生物标志物或选自下组的生物标志物组合，所述生物标志物是由两性调节蛋白，表皮生长因子，转化生长因子 α和来自患者的生物样品中的HER2生物标志物，并通过评估第一步的结果预测患者中用HER抑制剂治疗的反应。 公开了其中使用这些标记的其它用途和方法。
-
公开(公告)号：US20130323247A1
公开(公告)日：2013-12-05
申请号：US13127541
申请日：2009-11-06
申请人： Gerhard Zugmaier , Evelyn Degenhard
发明人： Gerhard Zugmaier , Evelyn Degenhard
IPC分类号： A61K39/395 , C07K16/46 , A61P35/02
CPC分类号： C07K16/2809 , C07K16/2803 , C07K16/468
摘要： The present invention relates to a method for the treatment, amelioration or elimination of acute lymphoblastic leukemia (ALL), the method comprising the administration of a pharmaceutical composition comprising a CD19xCD3 bispecific single chain antibody construct to an adult patient in the need thereof.
摘要翻译： 本发明涉及一种治疗，改善或消除急性淋巴细胞白血病（ALL）的方法，所述方法包括向需要的成年患者施用包含CD19xCD3双特异性单链抗体构建体的药物组合物。
-
公开(公告)号：US07700299B2
公开(公告)日：2010-04-20
申请号：US11438033
申请日：2006-05-19
IPC分类号： G01N33/53 , G01N33/48 , G01N33/566 , G01N33/567
CPC分类号： G01N33/57415 , C12Q1/6886 , C12Q2600/106 , C12Q2600/136 , C12Q2600/158 , G01N33/6872 , G01N2333/4756 , G01N2333/485 , G01N2333/495 , G01N2800/52
摘要： The invention is related to a method of predicting the response to a treatment with a HER inhibitor in a patient comprising the steps of assessing a biomarker or a combination of biomarkers selected from the group consisting of amphiregulin, an epidermal growth factor, a transforming growth factor alpha, and a HER2 biomarker in a biological sample from the patient and predicting the response to the treatment with the HER inhibitor in the patient by evaluating the results of the first step. Further uses and methods wherein these markers are used are disclosed.
摘要翻译： 本发明涉及预测患者中用HER抑制剂治疗反应的方法，其包括以下步骤：评估生物标志物或生物标志物的组合，所述生物标志物或选自下组的生物标志物组合，所述生物标志物是由两性调节蛋白，表皮生长因子，转化生长因子 α和来自患者的生物样品中的HER2生物标志物，并通过评估第一步的结果预测患者中用HER抑制剂治疗的反应。 公开了其中使用这些标记的其它用途和方法。
-
-
-
-
-
-
-
-
-
搜索结果
10 条记录 (耗时 0.011 秒)